Taiwan · Delayed Price · Currency is TWD Taiyen Biotech Statistics
Total Valuation
Taiyen Biotech has a market cap or net worth of TWD 6.42 billion. The enterprise value is 4.57 billion.
| Market Cap | 6.42B |
| Enterprise Value | 4.57B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | Aug 24, 2026 |
Share Statistics
Taiyen Biotech has 200.00 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 200.00M |
| Shares Outstanding | 200.00M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 4.41% |
| Float | 91.92M |
Valuation Ratios
The trailing PE ratio is 16.55.
| PE Ratio | 16.55 |
| Forward PE | n/a |
| PS Ratio | 2.01 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 25.68 |
| P/OCF Ratio | 11.60 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.69, with an EV/FCF ratio of 18.27.
| EV / Earnings | 11.72 |
| EV / Sales | 1.43 |
| EV / EBITDA | 6.69 |
| EV / EBIT | 10.74 |
| EV / FCF | 18.27 |
Financial Position
The company has a current ratio of 2.48, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.48 |
| Quick Ratio | 2.06 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.45 |
| Interest Coverage | 141.55 |
Financial Efficiency
Return on equity (ROE) is 5.87% and return on invested capital (ROIC) is 6.84%.
| Return on Equity (ROE) | 5.87% |
| Return on Assets (ROA) | 3.17% |
| Return on Invested Capital (ROIC) | 6.84% |
| Return on Capital Employed (ROCE) | 5.89% |
| Weighted Average Cost of Capital (WACC) | 4.92% |
| Revenue Per Employee | 7.09M |
| Profits Per Employee | 865,613 |
| Employee Count | 450 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 5.28 |
Taxes
In the past 12 months, Taiyen Biotech has paid 90.75 million in taxes.
| Income Tax | 90.75M |
| Effective Tax Rate | 18.89% |
Stock Price Statistics
The stock price has decreased by -3.15% in the last 52 weeks. The beta is 0.13, so Taiyen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -3.15% |
| 50-Day Moving Average | 31.94 |
| 200-Day Moving Average | 31.75 |
| Relative Strength Index (RSI) | 61.14 |
| Average Volume (20 Days) | 168,124 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Taiyen Biotech had revenue of TWD 3.19 billion and earned 389.53 million in profits. Earnings per share was 1.94.
| Revenue | 3.19B |
| Gross Profit | 1.26B |
| Operating Income | 425.06M |
| Pretax Income | 480.27M |
| Net Income | 389.53M |
| EBITDA | 673.75M |
| EBIT | 425.06M |
| Earnings Per Share (EPS) | 1.94 |
Balance Sheet
The company has 1.97 billion in cash and 112.22 million in debt, with a net cash position of 1.85 billion or 9.27 per share.
| Cash & Cash Equivalents | 1.97B |
| Total Debt | 112.22M |
| Net Cash | 1.85B |
| Net Cash Per Share | 9.27 |
| Equity (Book Value) | 6.71B |
| Book Value Per Share | 33.55 |
| Working Capital | 1.72B |
Cash Flow
In the last 12 months, operating cash flow was 553.60 million and capital expenditures -303.64 million, giving a free cash flow of 249.96 million.
| Operating Cash Flow | 553.60M |
| Capital Expenditures | -303.64M |
| Depreciation & Amortization | 248.69M |
| Net Borrowing | -28.74M |
| Free Cash Flow | 249.96M |
| FCF Per Share | 1.25 |
Margins
Gross margin is 39.40%, with operating and profit margins of 13.33% and 12.21%.
| Gross Margin | 39.40% |
| Operating Margin | 13.33% |
| Pretax Margin | 15.06% |
| Profit Margin | 12.21% |
| EBITDA Margin | 21.12% |
| EBIT Margin | 13.33% |
| FCF Margin | 7.84% |
Dividends & Yields
This stock pays an annual dividend of 1.40, which amounts to a dividend yield of 4.35%.
| Dividend Per Share | 1.40 |
| Dividend Yield | 4.35% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 66.75% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 4.35% |
| Earnings Yield | 6.07% |
| FCF Yield | 3.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 16, 2013. It was a reverse split with a ratio of 0.719181284.
| Last Split Date | Dec 16, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.719181284 |
Scores
Taiyen Biotech has an Altman Z-Score of 3.46 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.46 |
| Piotroski F-Score | 5 |